Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › cannabis

cannabis

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of cannabis

14 trials tracked of cannabis: 1 in phase 3 or 4.

14Trials tracked
1Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 3 1 Phase 2 6 Phase 1 7
  1. Phase 3 Vaping THC From Electronic Cigarettes Completed
  2. Phase 2 Vaporized Cannabis for Chronic Pain Associated With Sickle Cell Disease Completed
  3. Phase 2 The Impact and Detection of Driving Impairments Associated With Acute Cannabis Smoking Completed
  4. Phase 2 Effects of Vaporized Marijuana on Neuropathic Pain Completed
  5. Phase 2 Effects of Marijuana on Symptoms of OCD Completed
  6. Phase 2 Acute Effects of Cannabis on Cognition and Mobility in Older HIV-infected and HIV-Un-infected Women Completed
Show 8 more trials
  1. Phase 2 Effect of Cannabis and Endocannabinoids on HIV Neuropathic Pain Completed
  2. Phase 1 Differences in Cannabis Impairment and Its Measurement Due to Route of Administration Completed
  3. Phase 1 Brain Imaging of Cannabinoid Receptors Completed
  4. Phase 1 Pharmacokinetic and Pharmacodynamic Effects of Passive Cannabis Inhalation Completed
  5. Phase 1 Behavioral Pharmacology of Cannabis and Nicotine Completed
  6. Phase 1 Cannabis and Schizophrenia: Self-Medication and Agonist Treatment Completed
  7. Phase 1 Opioid and Cannabinoid Pharmacokinetic Interactions Completed
  8. Phase 1 Imaging the Neurochemistry of Drug Addiction With PET Completed

Showing the 14 most-cited and recently-updated of 14 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
High-potency cannabis products are consistently linked to increased risks of psychosis and anxiety symptoms
Psychiatry Sys. Review
High-potency cannabis products are consistently linked to increased risks of psychosis and anxiety symptoms High Potency Cannabis Linked to Increased Risk of Psychosis
This narrative review examines the mental health consequences of contemporary high-potency cannabis use in Europe. The authors synthesize ev…
New research highlights a consistent link between high-potency cannabis products and increased risks of psychosis, anxiety, and panic sympto…
Frontiers Jun 10, 2026
Systematic review of adolescent cannabis use links elevated addiction risk and neurodevelopmental concerns compared to adult onset
Psychiatry Meta-analysis
Systematic review of adolescent cannabis use links elevated addiction risk and neurodevelopmental concerns compared to adult onset Teenage cannabis use may reshape the developing brain in lasting ways
This systematic review synthesizes evidence from 8,432 participants across longitudinal studies regarding adolescent cannabis use versus adu…
Teen cannabis use may shrink key brain areas and raise addiction risk more than adult use.
Frontiers Apr 27, 2026
Meta-analysis identifies shared genetic loci between cannabis use and sleep disorders
Genetics & Precision Medicine Meta-analysis
Meta-analysis identifies shared genetic loci between cannabis use and sleep disorders Your Brain on Cannabis and Sleep: The Hidden Link
This meta-analysis of All of Us and UK Biobank cohorts investigated genetic correlations between cannabis use and sleep disorders.
Shared genes link cannabis use and sleep problems like insomnia, revealing why millions self-medicate and pointing to new treatment paths.
medRxiv Apr 18, 2026